United States
US 12,702,658 B2
Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C
US 12,702,658 B2 is a granted patent from the United States Patent and Trademark Office (USPTO), dated 2026-08-11. Applicant: Astex Therapeutics Ltd.; TAIHO PHARMACEUTICAL CO., LTD. Its PDF downloads from this page without an account, up to 5 a day.
- Applicant
- Astex Therapeutics Ltd.; TAIHO PHARMACEUTICAL CO., LTD.
- Inventors
- Tetsuya ABE; Yoko NAKATSURU; Hiroshi SOOTOME
- Publication date
- 2026-08-11
- Filing date
- 2022-10-24
- Document type
- B2 Granted patent
- Also written as
- US 12,702,658 B2 · US12702658 · 12702658
Abstract
A method of treating cancer comprises administering: (a) a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof; and (b) a therapeutically effective amount of an additional anti-cancer agent, to a subject in need of such treatment, the compound of Formula (I) being: where X, R1, R2, ring A, L1, L2, L3, and R5 are as defined in this disclosure.
The opening of the abstract. The full text is in the PDF.
No account needed: 5 free downloads a day (5 left today). Batch downloads and Office Action citations need a free account.
Patent office website: United States Patent and Trademark Office (USPTO)
Look up another patent
Need many patents at once?
Paste a whole list of numbers. DownloadPatent finds the right version of each and packs the PDFs into one ZIP.
Sign up free